{
    "clinical_study": {
        "@rank": "36942", 
        "arm_group": [
            {
                "arm_group_label": "Group A", 
                "arm_group_type": "Experimental", 
                "description": "single administration : amlodipine/valsartan 10/160mg, qd, 10days(oral)"
            }, 
            {
                "arm_group_label": "Group B", 
                "arm_group_type": "Experimental", 
                "description": "single administration : atorvastatin  40mg, qd, 7days(oral)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to assess the pharmacokinetic interactions between amlodipine\n      besylate/valsartan and atorvastatin single or co-administered in healthy volunteers."
        }, 
        "brief_title": "Pharmacokinetic Interactions Between Amlodipine Besylate/Valsartan and Atorvastatin in Healthy Male Subjects", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male volunteers in the age between 20 and 45 years old\n\n          2. The weight is over 55kg and is not exceed \u00b120% of ideal weight Ideal weight = [height\n             -100]*0.9\n\n          3. Subjects with no history of any significant chronic disease\n\n          4. Judged to be in good health on the basis of routine laboratory data obtained prior to\n             study drug administration\n\n          5. Willing to adhere to protocol requirements and sign a informed consent form\n\n        Exclusion Criteria:\n\n          1. Subjects with Symptoms of acute disease within 28days prior to study medication\n             dosing\n\n          2. Subjects with a history of gastrointestinal diseases which might significantly change\n             ADME of medicines\n\n          3. Subjects with a history of clinically significant allergies including drug allergies\n             or anaphylaxis to amlodipine, valsartan and/or atorvastatin\n\n          4. Subjects with a history of myopathy\n\n          5. Subjects with a hereditary problems, for example, galactose intolerance, Lapp lactase\n             deficiency or glucose-galactose malabsorption\n\n          6. Subject with the mean blood pressure of siDBP \u2265 150 mmHg or \u2264 90 mmHg and/or siSBP \u2265\n             95 mmHg or \u2264 50 mmHg at the screening visit\n\n          7. Subjects with abnormal HDL-cholesterol(<35mg/dL)\n\n          8. Subjects with abnormal of serum potassium concentration (<3.4 mEq/L of >5.5 mEq/L in\n             screening visit)\n\n          9. Subjects with a history of drug abuse\n\n         10. Subjects taking inducer or inhibitor of drug metabolism enzyme such as barbital\n             within 28days prior to study medication dosing\n\n         11. Subjects who have received any drugs that might confound the results of the trial\n             based on medical judgement by investigators within 14days prior to drug\n             administration and OTC or vitamin within 7days prior to drug administration\n\n         12. Participated in a previous clinical trial within 60 days prior to dosing\n\n         13. Donated blood within 60 days prior to dosing\n\n         14. Subjects with a history of alcohol abuse(over 21 units/week, 1 unit = 10 g of pure\n             alcohol) or is difficult to stop drinking within study\n\n         15. Subjects have ever smoked over 10 cigarette per day within 3 months prior to drug\n             administration\n\n         16. Subjects with a history of caffeine abuse or or is difficult to stop drinking within\n             study\n\n         17. Subjects with biliary obstruction\n\n         18. Subjects with hepatic dysfunction (AST or ALT >3 times to accepted normal range)\n\n         19. Subjects with moderate renal dysfunction (creatinine clearance (CLcr) < 30mL/min)\n\n         20. Subjects considered as unsuitable based on medical judgement by investigators"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "56", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02069821", 
            "org_study_id": "CJ_EXA_101"
        }, 
        "intervention": {
            "arm_group_label": [
                "Group A", 
                "Group B"
            ], 
            "description": "combination administration : amlodipine/valsartan 10/160mg and atorvastatin 40mg, qd, 10days(oral)", 
            "intervention_name": "combination administration", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Amlodipine", 
                "Valsartan", 
                "Amlodipine, valsartan drug combination", 
                "Atorvastatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 20, 2014", 
        "location": {
            "contact": {
                "email": "boniii@cnu.ac.kr", 
                "last_name": "Hong Jang Hee, assistant professor", 
                "phone": "+82-42-280-8718"
            }, 
            "facility": {
                "address": {
                    "city": "Daejeon", 
                    "country": "Korea, Republic of", 
                    "state": "Jung-gu", 
                    "zip": "301-721"
                }, 
                "name": "Chungnam national university hospital"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-label, Multiple-dosing, Two-arms, One-sequence Study to Evaluate the Safety and Pharmacokinetics After Co-administration of Exforge\u00ae (Amlodipine Besylate/Valsartan) and Lipitor\u00ae (Atorvastatin Ca) in Healthy Male Volunteers", 
        "overall_contact": {
            "email": "boniii@cnu.ac.kr", 
            "last_name": "Hong Jang Hee, assistant professor", 
            "phone": "+82-42-280-8718"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Korea: Ministry of Food and Drug Safety", 
                "Korea: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "AUCss,\u03c4, Css,max", 
                "measure": "To Evaluate PK interaction of amlodipine and valsartan", 
                "safety_issue": "No", 
                "time_frame": "from pre dosing to 24hr post dose"
            }, 
            {
                "description": "AUCss,\u03c4, Css,max", 
                "measure": "To Evaluate PK interaction of atorvastatin and 2-OH atorvastatin", 
                "safety_issue": "No", 
                "time_frame": "from pre dosing to 24hr post dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02069821"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "tss,max, CLss/F, Css,min", 
                "measure": "To Evaluate PK interaction of amlodipine and valsartan", 
                "safety_issue": "No", 
                "time_frame": "from pre dosing to 24hr post dose"
            }, 
            {
                "description": "tss,max, CLss/F, Css,min", 
                "measure": "To Evaluate PK interaction of atorvastatin and 2-OH atorvastatin", 
                "safety_issue": "No", 
                "time_frame": "from pre dosing to 24hr post dose"
            }
        ], 
        "source": "CJ HealthCare Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "CJ HealthCare Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}